CAS NO: | 618385-01-6 |
包装 | 价格(元) |
10 mM * 1 mL in DMSO | 电议 |
5mg | 电议 |
10mg | 电议 |
25mg | 电议 |
50mg | 电议 |
100mg | 电议 |
200mg | 电议 |
生物活性 | Vorapaxar (SCH 530348), an antiplatelet agent, is a selective, orally active, and competitivethrombinreceptorprotease-activated receptor(PAR-1)antagonist (Ki=8.1 nM). Vorapaxar (SCH 530348) inhibitsthrombinreceptor-activating peptide (TRAP)-induced platelet aggregation in a dose-dependent manner[1]. | ||||||||||||||||
IC50& Target | Ki: 8.1 nM (PAR-1)[1] | ||||||||||||||||
体外研究 (In Vitro) | Vorapaxar (SCH 530348) shows potent inhibition of thrombin-induced platelet aggregation with an IC50of 47 nM and haTRAP-induced platelet aggregation with an IC50of 25 nM. Vorapaxar (SCH 530348) inhibits thrombininduced calcium transient in human coronary artery smooth muscle cells (HCASMC) with a Kiof 1.1 nM. It also inhibits thrombin-stimulated thymidine incorporation in HCASMC with a Ki of 13 nM[1]. | ||||||||||||||||
Clinical Trial | |||||||||||||||||
分子量 | 492.58 | ||||||||||||||||
性状 | Solid | ||||||||||||||||
Formula | C29H33FN2O4 | ||||||||||||||||
CAS 号 | 618385-01-6 | ||||||||||||||||
中文名称 | 沃拉帕沙;维拉帕莎 | ||||||||||||||||
运输条件 | Room temperature in continental US; may vary elsewhere. | ||||||||||||||||
储存方式 |
| ||||||||||||||||
溶解性数据 | In Vitro: DMSO : 25 mg/mL(50.75 mM;Need ultrasonic) 配制储备液
* 请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液;一旦配成溶液,请分装保存,避免反复冻融造成的产品失效。 In Vivo: 请根据您的实验动物和给药方式选择适当的溶解方案。以下溶解方案都请先按照In Vitro方式配制澄清的储备液,再依次添加助溶剂: ——为保证实验结果的可靠性,澄清的储备液可以根据储存条件,适当保存;体内实验的工作液,建议您现用现配,当天使用;
以下溶剂前显示的百
|